Bristol-Myers Squibb Company

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +45

Bristol Myers Squibb stock gains support from pediatric Camzyos data

Clinical trial results Drug approval AI-generated analysis

πŸ“ˆ Bristol Myers Squibb presented positive 56-week results from the SCOUT-HCM trial for Camzyos in adolescents with symptomatic obstructive hypertrophic cardiomyopathy.

πŸ”¬ The study enrolled 44 patients aged 12 to under 18, demonstrating a mean Valsalva LVOT-gradient reduction of -48.1 mmHg after continuous mavacamten treatment.

βœ… Safety data remained consistent with prior results, with no new signals and no drop in left ventricular ejection fraction below 50% for any patient.

πŸ₯ The FDA previously approved Camzyos for pediatric patients weighing at least 30 kilograms in September 2026 based on earlier trial data.

πŸ’Ό The findings extend the commercial reach of Camzyos by validating its efficacy and safety in a younger demographic with obstructive hypertrophic cardiomyopathy.

πŸ“Š Bristol Myers Squibb shares traded at 55.65 euros, reflecting investor focus on the company's cardiovascular portfolio updates.

Bullish Signals
  • Bristol Myers Squibb presented robust 56-week data from the SCOUT-HCM trial showing a mean Valsalva LVOT-gradient reduction of -48.1 mmHg in adolescents treated with Camzyos.
  • The drug demonstrated consistent safety profiles over 56 weeks with no new safety signals and no instances of left ventricular ejection fraction falling below 50%.
  • Positive pediatric data extends the commercial reach of Camzyos, validating its use in adolescents following the FDA's September 2026 approval for patients weighing at least 30 kilograms.
Full Analysis
Bristol Myers Squibb (BMY) received positive attention following the presentation of 56-week data from the Phase 3 SCOUT-HCM trial for its drug Camzyos (mavacamten). The study, presented at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions in Chicago, focused on adolescents aged 12 to under 18 with symptomatic obstructive hypertrophic cardiomyopathy. These results extend the evidence base for Camzyos shortly after the FDA granted pediatric approval in September 2026 for patients weighing at least 30 kilograms. The trial enrolled 44 patients, with most receiving continuous treatment with mavacamten. At Week 56, the group recorded a mean reduction in Valsalva LVOT-gradient of -48.1 mmHg, indicating significant improvement in blood flow obstruction. Safety findings remained consistent with earlier data, showing no new safety signals and no instances of left ventricular ejection fraction dropping below 50% during the evaluation period. The company highlighted that the longer-term data supports the continued evaluation of Camzyos in this pediatric population. While the trial remains a clinical efficacy study rather than a financial forecast, the findings bolster the commercial reach of the cardiovascular medicine by validating its use in adolescents. This development reinforces BMY's position in treating obstructive hypertrophic cardiomyopathy across adult and pediatric demographics.